Great Novel Therapeutics Biotech & Medicals reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 0.54 million compared to TWD 0.63 million a year ago. Net loss was TWD 55.78 million compared to TWD 35.86 million a year ago.

Basic loss per share from continuing operations was TWD 2.31 compared to TWD 1.7 a year ago. Diluted loss per share from continuing operations was TWD 2.31 compared to TWD 1.7 a year ago.